Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year

Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz has lead to Yahoo Finance naming Novo Nordisk its 2023 Company of the Year. Novo Nordisk CEO Lars Fruergaard Jorgensen spoke with Yahoo Finance Senior Health Reporter Anjalee Khemlani and Yahoo Finance reporters take a closer look at the success and impacts on December 11, 2023.
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
Get the latest news and data at finance.yahoo.com
Download the Yahoo Finance app on Apple (apple.co/3Rten0R) or Android (bit.ly/3t8UnXO)
Follow Yahoo Finance on social:
X: / yahoofinance
Instagram: www.instagram....
TikTok: www.tiktok.com...
Facebook: / yahoofinance
LinkedIn: / yahoo-finance
#novonordisk #ozempic #wegovy #yahoofinance

[@RpgmaniacNo1]

Great company and a high quality long-term stock. Interestingly , the only Pharma company I know, without goodwill in the balance sheet. But the stock is very expensive and the fair value of the stock is currently uncertain.

[@spatty2589]

I have this stockNVO and LLY but they fluctuate a lot. I would like to understand why?

[@Phearsum]

Constant buying/selling day in and day out tend to cause rapid fluctuations in price.

[@JoseReyes-hz6xm]

Yes

[@michayng4105]

to tackle obesity problem, i propose that government should ban high levels of sugar in food, specially supermarket processed food

[@t1uan98]

The money they make from sugar out weighs the cost of obesity.

[@JoseReyes-hz6xm]

Hey

[@JoseReyes-hz6xm]

Bitcoin go up soon

[@rothsshvili5125]

Pourquoi?